ACR 23

Information from the debate on what is the best treatment option for Giant Cell Arteritis and Polymyalgia Rheumatica, generated during ACR 2023, is synthesized by Dr. Spiera.

What is the safety profile of some RA drugs? Dr. Burmester presents the Taiwanese group's study on this striking topic.

What are the proteins to look for when considering treatment in patients with RA in the future? How has the inclusion of autoantibodies and serum complexes in symptoms such as inflammatory joint pain been redefined in considering the diagnosis and treatment of a patient who may have RA?

Rituximab and mycophenolate vs. hematopoietic stem cell transplantation, reports of studies show efficacy and safety data on this type of treatment, the highlights of which are presented by Dr. Spiera in the video.

The principles for creating, preparing and producing a postcast were presented during the lecture by Dr. Hausmman, Harvard University, and Dr. Burmester summarises them in 6 important aspects.

Learn about the benefits of CAR-T cells in different autoimmune diseases, summarised by Dr. Peter Nash

Dr. Eduardo Mysler presents the results of the post hoc analysis of efficacy and safety of Tofacitinib in patients with ankylosing spondylitis according to C-reactive protein levels.

New ways of diagnosing RA are being achieved through AI that allows the creation of accurate models and algorithms to be certain that the patient has the disease. Dr Nash shares some of the most relevant highlights on the topic presented at ACR 2023.